43 recruiting, 29 active not recruiting, 10 terminated, 8 completed. 65 Phase 2, 24 Phase 3, 21 Phase 1, 10 Not applicable.
Follow Bone Scan: new trials by email Literature Review of Bone Scan trials Research Report on Bone Scan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Investigational Medication Pembrolizumab After Kidney Removal for Patients With Non-Clear Cell Renal Cell Carcinoma Biospecimen Collection, Bone Scan, Computed Tomography - Non-Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8 | Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 400 | 2027-02-10 | 2026-07-08 |
| Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate Cancer Abiraterone Acetate, Biospecimen Collection, Bone Scan - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 / Phase 3 | Not yet recruiting | ECOG-ACRIN Cancer Research Group | 432 | 2027-01-06 | 2026-10-01 |
| Biology Guided Therapy Recommendations for Treatment Determination of Hormone Receptor-Positive Advanced, Unresectable or Metastatic Breast Cancer, ENDORSE Trial Biopsy Procedure, Biospecimen Collection, Bone Scan - Advanced Hormone Receptor-Positive Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8 | Phase 1 | Not yet recruiting | City of Hope Medical Center | 20 | 2026-12-19 | 2026-05-15 |
| Zanzalintinib and MO-03 for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy Biospecimen Collection, Bone Scan, C. butyricum CBM 588 Probiotic Strain Capsule Formulation MO-03 - Metastatic Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8 | Phase 2 | Not yet recruiting | City of Hope Medical Center | 34 | 2026-11-28 | 2026-05-11 |
| Pluvicto for the Treatment of African American Men With Metastatic Castration-Resistant Prostate Cancer Biopsy Procedure, Biospecimen Collection, Bone Scan - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 | Not yet recruiting | Emory University | 88 | 2026-11-02 | 2026-10-06 |
| Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial Androgen Receptor Pathway Inhibitor, Transdermal Estrogen, Bone Scan - Castration-Sensitive Prostate Adenocarcinoma, Metastatic Castration-Sensitive Prostate Adenocarcinoma | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 60 | 2026-11-01 | 2026-10-16 |
| IL-18 Armored STEAP1 CAR T Cells for the Treatment of Metastatic Castration Resistant Prostate Cancer FH-STEAP1 IL-18 CAR T cells, Antiandrogen Therapy, Biospecimen Collection - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 1 | Not yet recruiting | Fred Hutchinson Cancer Center | 20 | 2026-10-31 | 2026-09-04 |
| Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones Biospecimen Collection, Bone Scan, Computed Tomography - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma | Phase 1 | Withdrawn | National Cancer Institute (NCI) | 2026-10-01 | 2026-08-28 | |
| Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | Children's Oncology Group | 1708 | 2026-08-28 | 2026-07-30 |
| Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial Anastrozole, Biospecimen Collection, Bone Scan - Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 3 | Recruiting | National Cancer Institute (NCI) | 1978 | 2026-08-10 | 2026-10-26 |
| A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS) Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Rhabdomyosarcoma | Phase 3 | Recruiting | Children's Oncology Group | 342 | 2026-07-14 | 2026-08-25 |
| Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases Zanzalintinib, Investigator Choice of Bone Strengthening Agents (BSA), Non-Investigational Radiation Therapy (RT) - Clear Cell Renal Cell Cancer (ccRCC), Clear Cell Renal Carcinoma | Phase 2 | Recruiting | Kelly Fitzgerald, MD | 20 | 2026-06-10 | 2026-07-27 |
| Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer Axitinib, Biospecimen Collection, Bone Scan - Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma | Phase 3 | Recruiting | SWOG Cancer Research Network | 718 | 2026-06-05 | 2026-06-11 |
| Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer Biopsy, Biospecimen Collection, Bone Scan - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | University of Michigan Rogel Cancer Center | 20 | 2026-06-01 | 2026-05-05 |
| Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial Lutetium Lu 177 Vipivotide Tetraxetan, Biospecimen Collection, Patient Monitoring - Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 3 | Recruiting | Alliance for Clinical Trials in Oncology | 1524 | 2026-03-31 | 2026-10-02 |
| Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer Biospecimen Collection, Bone Scan, Computed Tomography - Advanced Clear Cell Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma | Phase 1 | Recruiting | City of Hope Medical Center | 33 | 2026-03-23 | 2026-07-16 |
| 177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer Biospecimen Collection, Bone Scan, Computed Tomography - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 1 | Recruiting | City of Hope Medical Center | 30 | 2026-03-06 | 2026-04-20 |
| Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial Androgen Therapy, Apalutamide, Docetaxel - Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 3 | Recruiting | Alliance for Clinical Trials in Oncology | 1260 | 2025-12-01 | 2026-10-02 |
| High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer Radiation Therapy, Pembrolizumab, Nab-paclitaxel - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma | Phase 2 | Recruiting | Emory University | 29 | 2025-10-22 | 2026-04-17 |
| Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer Biospecimen Collection, Bone Scan, Capecitabine - Anatomic Stage IV Breast Cancer AJCC v8, Estrogen-receptor-positive Breast Cancer | Phase 2 | Recruiting | Mayo Clinic | 35 | 2025-10-01 | 2026-08-12 |
Showing 20 of 109. Sign in to see all of them.
Prostatic Neoplasms (47) · Carcinoma, Renal Cell (15) · Breast Neoplasms (7) · Urinary Bladder Neoplasms (6) · Carcinoma, Transitional Cell (5) · Clear-cell metastatic renal cell carcinoma (5) · Rhabdomyosarcoma (5) · Wilms Tumor (5) · Central Nervous System Neoplasms (4) · Ependymoma (4) · Glioma (4) · Hepatoblastoma (4) · Histiocytosis, Langerhans-Cell (4) · Lymphoma, Non-Hodgkin (4) · Medulloblastoma (4)
National Cancer Institute (NCI) (35) · City of Hope Medical Center (9) · Children's Oncology Group (8) · Mayo Clinic (7) · NRG Oncology (6) · Fred Hutchinson Cancer Center (5) · University of Washington (4) · Alliance for Clinical Trials in Oncology (3) · Emory University (3) · OHSU Knight Cancer Institute (3) · Central Hospital, Nancy, France (2) · SWOG Cancer Research Network (2) · The European Uro-Oncology Group (2) · ECOG-ACRIN Cancer Research Group (1) · East and North Hertfordshire NHS Trust (1)
United States (94) · Canada (22) · Puerto Rico (15) · Australia (11) · New Zealand (5) · France (3) · Hong Kong (3) · Netherlands (3) · Singapore (3) · Saudi Arabia (2) · Belgium (1) · China (1) · Germany (1) · Ireland (1) · Italy (1)
Michael Schweizer (4) · Sumanta K Pal (4) · Alex Chehrazi-Raffle, MD (2) · Andrea B Apolo (2) · Rosa Nadal Rios, MD, PhD (2) · Susanne Osanto, MD PhD (2) · Alexander N Shoushtari (1) · Alice Lee (1) · Andrei Iagaru, MD (1) · Angela Castellanos Rodriguez, MD, MSc (1) · Anish Thomas, M.D. (1) · Anthony A Bavry, MD MPH (1) · Ardaman Shergill (1) · Arthur Hung (1) · Bassel Nazha, MD, MPH (1)
PMID 23455520, PMID 26405167, PMID 26956325, PMID 30227893, PMID 31236756, PMID 31401903, PMID 32897402, PMID 33078998, PMID 33591402, PMID 33592176, PMID 33602696, PMID 33604999, PMID 34486544, PMID 35031545, PMID 35304832, PMID 35353553, PMID 35383907, PMID 37146227, PMID 38421243, PMID 39255440, PMID 39938471, PMID 40170372, PMID 41166674, PMID 41338644, PMID 41671463, PMID 41785440, PMID 42117295, PMID 42498485, PMID 42507969, PMID 42686334, PMID 42820295
U10CA180886 (13), U10CA180821 (10), P30CA033572 (9), U10CA180868 (9), U10CA180888 (5), U10CA180820 (4), P30CA138292 (3), UM1CA186644 (3), UM1CA186689 (3), P50CA097186 (2), UM1CA186691 (2), P30CA016672 (1), P30CA060553 (1), P30CA168524 (1), R01CA283603 (1)